AR052215A1 - 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen. - Google Patents

3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen.

Info

Publication number
AR052215A1
AR052215A1 ARP050102675A ARP050102675A AR052215A1 AR 052215 A1 AR052215 A1 AR 052215A1 AR P050102675 A ARP050102675 A AR P050102675A AR P050102675 A ARP050102675 A AR P050102675A AR 052215 A1 AR052215 A1 AR 052215A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
cycloalkyl
halo
haloalkoxy
Prior art date
Application number
ARP050102675A
Other languages
English (en)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR052215A1 publication Critical patent/AR052215A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Estos compuestos y las composiciones de éstos, son utiles en el tratamiento de enfermedades relacionadas con la expresion y/o la actividad del receptor de quimioquina. Reivindicacion 1: Un compuesto de formula (1) o una sal o una prodroga de éste aceptable para el uso farmacéutico, caracterizado porque: una línea con guiones indica un enlace opcional; W es como se muestra en las formula (2); V es N, NO o CR5; X es N, NO o CR2; Y es N, NO o CR3; Z es N, NO o CR4; donde no más de uno de V, X, Y y Z es NO; RA, RA1, RB y RB1 son cada uno independientemente H, OH, halo, C1-6 alquilo, C1-6 alquenilo, C1-6 alquinilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 haloalcoxilo, heterociclilo, carbociclilo, NR10R12, NR10CO2R11; NR10CONR10R12; NR10SO2NR10R12, NR10-SO2-R11, CN, CONR10R12, CO2R10, NO2, SR10, SOR10, SO2R10 o SO2-NR10R12; R1 es C1-6 alquilo, C1-6 haloalquilo, C1-6 hidroxialquilo, -(C0-6 alquil)-O-(C1-6 alquilo), -(C0-6 alquil)-S-(C1-6 alquilo), -(C0-6 alquil)-(C3-7 cicloalquil)-(C0-6 alquilo), OH, OR10, SR10, COR11, CO2R10, CONR10R12, carbociclilo, heterociclilo, CN, NR10R12, NR10SO2R10, NR10COR10, NR10CO2R10, NR10CONR12, CR10R11CO2R10 o CR10R11OCOR10; R2, R3, R4, R5 y R6 son cada uno independientemente H, OH, halo, C1-6 alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 haloalcoxilo, C1-6 tioalquilo, NR10R12, NR10CO2R10, NR10CONR10R12; NR10SO2NR10R12, NR10-SO2-R11, heterociclilo, carbociclilo, carbocicliloxilo, heterocicliloxilo, CN, NO2, COR11, CONR10R12, CO2R10, NO2, SR10, SOR10, SO2R10; o SO2-NR10R12; R7 es H o C1-6 alquilo opcionalmente sustituido por 1-3 sustituyentes seleccionados entre halo, OH, CO2H, CO2-(C1-6 alquilo), o C1-3 alcoxilo; R8 es C1-3 alcoxilo, C1-3 haloalcoxilo, C3- 6cicloalquiloxilo u OH; R8' es H; R9 y R9' son cada uno independientemente H, C1-6 alquilo, halo, C1-3 alcoxilo, C1-3 haloalcoxilo, C3-6 cicloalquilo, C3-6 cicloalquiloxilo, OH, CO2R10, OCOR10, donde dicho C1-6 alquilo está opcionalmente sustituido con uno o más sustituyentes seleccionados entre F, C1-3 alcoxilo, OH o CO2R10; o R9 y R9', junto con el átomo de C al que están unidos, forman un grupo espirocíclico de 3-7 miembros; R10 es H, C1-6 alquilo, bencilo, fenilo, o C3-6 cicloalquilo, donde dicho C1-6 alquilo, bencilo, fenilo, o C3-6 cicloalquilo está opcionalmente sustituido con 1-3 sustituyentes seleccionados entre halo, OH, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxilo, C1-3 haloalcoxilo, CO2H y CO2-(C1-6)alquilo); R11 es H, OH, C1-6 alquilo, C1-6 alcoxilo, bencilo, fenilo, benciloxilo, feniloxilo, C3-6 cicloalquilo o C3-6 cicloalquiloxilo, donde dicho C1-6 alquilo, C1-6 alcoxilo, bencilo, fenilo, benciloxilo, feniloxilo, C3-6 cicloalquilo o C3-6 cicloalquiloxilo, está opcionalmente sustituido con 1-3 sustituyentes seleccionados entre halo, OH, C1-3 alquilo, C1-3 alcoxilo, CO2H, CO2-(C1-6 alquilo) y CF3; R12 es H, C1-6 alquilo, bencilo, fenilo, o C3-6 cicloalquilo, donde dicho C1-6 alquilo, bencilo, fenilo, o C3-6 cicloalquilo está opcionalmente sustituido con 1-3 sustituyentes seleccionados entre halo, OH, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxilo, C1-3 haloalcoxilo, CO2H, y CO2-(C1-6 alquilo); y p es 0 o 1.
ARP050102675A 2004-06-28 2005-06-28 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen. AR052215A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58348204P 2004-06-28 2004-06-28
US62448104P 2004-11-01 2004-11-01

Publications (1)

Publication Number Publication Date
AR052215A1 true AR052215A1 (es) 2007-03-07

Family

ID=35783315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102675A AR052215A1 (es) 2004-06-28 2005-06-28 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen.

Country Status (22)

Country Link
US (2) US7618970B2 (es)
EP (1) EP1763347A4 (es)
JP (2) JP4116671B2 (es)
KR (1) KR100856155B1 (es)
CN (1) CN102382088A (es)
AP (1) AP2006003848A0 (es)
AR (1) AR052215A1 (es)
AU (1) AU2005259983B2 (es)
BR (1) BRPI0512634A (es)
CA (1) CA2571397C (es)
CR (1) CR8759A (es)
EA (1) EA012649B1 (es)
EC (1) ECSP067121A (es)
GE (1) GEP20094844B (es)
IL (1) IL179735A0 (es)
MA (1) MA28681B1 (es)
MX (1) MXPA06014673A (es)
NO (1) NO20070489L (es)
NZ (1) NZ551673A (es)
TW (1) TWI366458B (es)
UA (1) UA83311C2 (es)
WO (1) WO2006004741A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050024A2 (en) 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
HU229709B1 (en) 2004-04-13 2014-05-28 Incyte Corp Wilmington Piperazinyilpiperidine derivatives as chemokine receptor antagonists
MXPA06014673A (es) * 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarbozamidas como moduladores de receptores de quimioquinas.
TW200608966A (en) * 2004-06-28 2006-03-16 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
MEP1008A (xx) * 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5292400B2 (ja) 2007-07-24 2013-09-18 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体
EP2173713B1 (en) * 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
AU2009321221B2 (en) * 2008-11-26 2013-04-04 Pfizer Inc. 3-aminocyclopentanecarboxamides as chemokine receptor modulators
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
JP5544626B2 (ja) * 2009-02-27 2014-07-09 国立大学法人 鹿児島大学 間質性肺炎治療剤
NZ599770A (en) * 2009-12-17 2014-06-27 Boehringer Ingelheim Int New ccr2 receptor antagonists and uses thereof
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
DK3177612T3 (da) 2014-08-04 2022-05-16 Nuevolution As Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5473400A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6977265B2 (en) * 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
SI1501507T1 (sl) 2002-04-29 2008-12-31 Merck & Co Inc Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US7166614B2 (en) 2002-04-29 2007-01-23 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
US7247725B2 (en) 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
CA2503844A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
CA2503713A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
AU2003286701B2 (en) * 2002-10-30 2008-12-18 Merck Sharp & Dohme Corp. Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
US7491737B2 (en) 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
WO2004050024A2 (en) 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
BR0317445A (pt) * 2002-12-20 2005-11-16 Leo Pharma As Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20060101476A (ko) 2003-10-27 2006-09-25 머크 앤드 캄파니 인코포레이티드 Ｃｃｒ-2 길항제 염
CA2548393A1 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
WO2005060665A2 (en) 2003-12-18 2005-07-07 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
AU2004313486A1 (en) 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
WO2005070133A2 (en) 2004-01-20 2005-08-04 Merck & Co., Inc. 2,6-disubstituted piperidines as modulators of chemokine receptor activity
JP2007519734A (ja) 2004-01-28 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド アミノシクロペンチルピリドピラジノン系ケモカイン受容体活性調節剤
EP1742919A4 (en) 2004-04-26 2010-04-28 Merck Sharp & Dohme CYCLOPENTYL TETRAHYDROISOQUINOLINE 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROPYRANYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
MXPA06013112A (es) 2004-05-11 2007-02-14 Incyte Corp 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas.
MXPA06014673A (es) * 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarbozamidas como moduladores de receptores de quimioquinas.
TW200608966A (en) * 2004-06-28 2006-03-16 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors

Also Published As

Publication number Publication date
JP4116671B2 (ja) 2008-07-09
EA012649B1 (ru) 2009-12-30
IL179735A0 (en) 2007-05-15
NO20070489L (no) 2007-03-07
CN102382088A (zh) 2012-03-21
US7618970B2 (en) 2009-11-17
NZ551673A (en) 2010-11-26
BRPI0512634A (pt) 2008-03-25
CA2571397A1 (en) 2006-01-12
JP2008074878A (ja) 2008-04-03
EA200602243A1 (ru) 2007-04-27
UA83311C2 (en) 2008-06-25
EP1763347A4 (en) 2009-05-20
AU2005259983A1 (en) 2006-01-12
MA28681B1 (fr) 2007-06-01
KR20070024659A (ko) 2007-03-02
US20060020133A1 (en) 2006-01-26
AU2005259983B2 (en) 2011-07-28
KR100856155B1 (ko) 2008-09-03
CR8759A (es) 2006-12-13
MXPA06014673A (es) 2007-03-26
WO2006004741A2 (en) 2006-01-12
CA2571397C (en) 2012-05-22
TWI366458B (en) 2012-06-21
JP2008504298A (ja) 2008-02-14
ECSP067121A (es) 2007-01-26
EP1763347A2 (en) 2007-03-21
US8563582B2 (en) 2013-10-22
US20090208485A1 (en) 2009-08-20
TW200608960A (en) 2006-03-16
GEP20094844B (en) 2009-11-25
AP2006003848A0 (en) 2006-12-31
WO2006004741A3 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AR052215A1 (es) 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen.
AR049559A1 (es) 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas
AR116978A1 (es) Fungicidas de tolilo sustituido
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20070112A1 (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos
AR064355A1 (es) Herbicidas derivados de isoxazol
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR052938A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
AR057433A1 (es) Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica
AR078884A1 (es) Antagonistas del receptor crth2 basados en indol
AR059176A1 (es) Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.
AR092288A1 (es) Ligandos del receptor ep1
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20060457A1 (es) Derivados de difenil eter como antagonistas de los receptores 5ht2
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα

Legal Events

Date Code Title Description
FB Suspension of granting procedure